Sixiang Shi

University of Utah — United States

Engineering · Physical Sciences

34h-index4.5kcitations89works0.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Nanoplatforms for cancer theranostics(33), Nanoparticle-Based Drug Delivery(30), Extracellular vesicles in disease(11), Cancer Cells and Metastasis(10), Radiopharmaceutical Chemistry and Applications(10)

Publications89 total

Positron Emission Tomography of CD47/SIRPα Axis and Image-Informed Therapeutic Design
2026
FOLR1-targeted Actinium-225-based Alpha-particle Therapy Eliminates Ovarian Cancer
2025Open Access
Copper Sulfide Nanoparticle–Mediated Photothermolysis Induces Immunogenic Cell Death in Ovarian Cancer Cells
2025Open Access
Image-guided targeting of mitochondrial metabolism sensitizes pediatric malignant rhabdoid tumors to low-dose radiotherapy
Science Advances·2025· 2 citedOpen Access
Tumor agnostic ultrasmall nanoprobes for fluorescence-guided surgical resection in peritoneal metastasis
European Journal of Nuclear Medicine and Molecular Imaging·2024
Image-Guided Targeting of Mitochondrial Metabolism Sensitizes Pediatric Malignant Rhabdoid Tumors to Low Dose Radiotherapy
2024Open Access
Molecular imaging of innate immunity and immunotherapy
Advanced Drug Delivery Reviews·2023· 13 cited
Enhancing oral delivery of plant-derived vesicles for colitis
Journal of Controlled Release·2023· 14 citedOpen Access
Abstract 2720: Enhancing oral delivery of plant-derived vesicles
Cancer Research·2023
Supplementary methods, Supplementary tables 1 through 4, and Supplementary figure 1 from Comparison of the Superagonist Complex, ALT-803, to IL15 as Cancer Immunotherapeutics in Animal Models
2023Open Access
Data from Comparison of the Superagonist Complex, ALT-803, to IL15 as Cancer Immunotherapeutics in Animal Models
2023Open Access
Data from Comparison of the Superagonist Complex, ALT-803, to IL15 as Cancer Immunotherapeutics in Animal Models
2023Open Access
Supplementary methods, Supplementary tables 1 through 4, and Supplementary figure 1 from Comparison of the Superagonist Complex, ALT-803, to IL15 as Cancer Immunotherapeutics in Animal Models
2023Open Access
Supplementary Methods from Dual Targeting of Tissue Factor and CD105 for Preclinical PET Imaging of Pancreatic Cancer
2023Open Access
Supplementary Methods from Dual Targeting of Tissue Factor and CD105 for Preclinical PET Imaging of Pancreatic Cancer
2023Open Access
Data from Dual Targeting of Tissue Factor and CD105 for Preclinical PET Imaging of Pancreatic Cancer
2023Open Access
Movie S3 from Dual Targeting of Tissue Factor and CD105 for Preclinical PET Imaging of Pancreatic Cancer
2023Open Access
Supplementary Figures from Dual Targeting of Tissue Factor and CD105 for Preclinical PET Imaging of Pancreatic Cancer
2023Open Access
Movie S3 from Dual Targeting of Tissue Factor and CD105 for Preclinical PET Imaging of Pancreatic Cancer
2023Open Access
Movie S2 from Dual Targeting of Tissue Factor and CD105 for Preclinical PET Imaging of Pancreatic Cancer
2023Open Access
page 1 of 5Next →

Frequent Co-authors

Weibo Cai(38), Shreya Goel(20), Hao Hong(19), Todd E. Barnhart(17), Feng Chen(14), Stephen A. Graves(14), Charles P. Theuer(10), Hector F. Valdovinos(9), Reinier Hernandez(8), Haiming Luo(8), Zhuang Liu(7), Emily B. Ehlerding(7), Robert J. Nickles(7), Chun Li(7), Yin Zhang(5), Kai Yang(5), Hing C. Wong(5), Christopher G. England(5), Robert J. Nickles(5), Liang Cheng(4)